Suhan Aerosol, an Indian OTC drug maker, failed to test high-risk ingredients for toxic diethylene/ethylene glycol and lacked quality oversight.
What happened
FDA reviewed records Suhan Aerosol submitted after the agency's January 25, 2023 request under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act; there was no inspection. FDA found the firm did not test each shipment and lot of high-risk components such as glycerin, propylene glycol, and sorbitol for identity and for diethylene glycol (DEG) or ethylene glycol (EG) contamination. FDA also found the quality unit did not effectively approve or reject components, and the firm was placed on Import Alert 66-40 on March 30, 2023.
What FDA found
Suhan Aerosol did not test each incoming lot of high-risk components such as glycerin, propylene glycol, and sorbitol to verify identity and detect diethylene glycol (DEG) or ethylene glycol (EG) contamination.
21 CFR 211.84(d)(1)Suhan Aerosol's quality unit did not effectively exercise its authority to approve or reject components in the materials system.
21 CFR 211.22(a)
What FDA wants
FDA tells Suhan Aerosol to respond in writing within 30 working days with corrective actions and to provide DEG/EG test results within 30 calendar days. If corrective actions cannot be completed within 15 working days, the firm must state why and give a completion schedule.
Who should pay attention
- brands that buy OTC drugs or personal-care products from Suhan Aerosol
- companies sourcing children's toothpaste or hand sanitizer from contract manufacturers
- buyers and suppliers of glycerin, propylene glycol, or sorbitol
This is a summary. Read the original letter on fda.gov.